Arefayene M - Search Results

1

Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.

Bame E, Tang H, Burns JC, Arefayene M, Michelsen K, Ma B, Marx I, Prince R, Roach AM, Poreci U, Donaldson D, Cullen P, Casey F, Zhu J, Carlile TM, Sangurdekar D, Zhang B, Trapa P, Santoro J, Muragan P, Pellerin A, Rubino S, Gianni D, Bajrami B, Peng X, Coppell A, Riester K, Belachew S, Mehta D, Palte M, Hopkins BT, Scaramozza M, Franchimont N, Mingueneau M. Bame E, et al. Among authors: arefayene m. Clin Transl Immunology. 2021 Jun 14;10(6):e1295. doi: 10.1002/cti2.1295. eCollection 2021. Clin Transl Immunology. 2021. PMID: 34141433 Free PMC article.

2

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

Ma B, Bohnert T, Otipoby KL, Tien E, Arefayene M, Bai J, Bajrami B, Bame E, Chan TR, Humora M, MacPhee JM, Marcotte D, Mehta D, Metrick CM, Moniz G, Polack E, Poreci U, Prefontaine A, Sheikh S, Schroeder P, Smirnakis K, Zhang L, Zheng F, Hopkins BT. Ma B, et al. Among authors: arefayene m. J Med Chem. 2020 Nov 12;63(21):12526-12541. doi: 10.1021/acs.jmedchem.0c00702. Epub 2020 Aug 6. J Med Chem. 2020. PMID: 32696648

3

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

Brian W, Tremaine LM, Arefayene M, de Kanter R, Evers R, Guo Y, Kalabus J, Lin W, Loi CM, Xiao G. Brian W, et al. Among authors: arefayene m. Pharmacogenomics. 2016 Apr;17(6):615-31. doi: 10.2217/pgs.16.9. Epub 2016 Apr 5. Pharmacogenomics. 2016. PMID: 27045656 Review.

4

Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.

Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA. Desai M, et al. Among authors: arefayene m. Pharmacogenomics J. 2003;3(2):105-13. doi: 10.1038/sj.tpj.6500160. Pharmacogenomics J. 2003. PMID: 12746736 Clinical Trial.

5

Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19.

Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, Nguyen A, Desta Z, Flockhart DA. Arefayene M, et al. Pharmacogenetics. 2003 Apr;13(4):199-206. doi: 10.1097/00008571-200304000-00004. Pharmacogenetics. 2003. PMID: 12668916

6

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD. Pinto AG, et al. Among authors: arefayene m. Clin Pharmacol Ther. 2005 Mar;77(3):178-88. doi: 10.1016/j.clpt.2004.10.002. Clin Pharmacol Ther. 2005. PMID: 15735612 Clinical Trial.

7

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.

Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, Flockhart DA, Wilkes DS, Skaar TC. Arefayene M, et al. Pharmacogenet Genomics. 2009 Jun;19(6):464-76. doi: 10.1097/fpc.0b013e32832c005a. Pharmacogenet Genomics. 2009. PMID: 19514129

8

Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.

Shin JG, Kang WK, Shon JH, Arefayene M, Yoon YR, Kim KA, Kim DI, Kim DS, Cho KH, Woosley RL, Flockhart DA. Shin JG, et al. Among authors: arefayene m. Br J Clin Pharmacol. 2007 Feb;63(2):206-15. doi: 10.1111/j.1365-2125.2006.02793.x. Epub 2006 Nov 10. Br J Clin Pharmacol. 2007. PMID: 17096683 Free PMC article. Clinical Trial.

9

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG. Takada K, et al. Among authors: arefayene m. Arthritis Rheum. 2004 Jul;50(7):2202-10. doi: 10.1002/art.20338. Arthritis Rheum. 2004. PMID: 15248218 Free article.

10

A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy Volunteers.

Zuo P, Arefayene M, Pan WJ, Freshwater T, Monteleone J. Zuo P, et al. Among authors: arefayene m. Clin Pharmacol Drug Dev. 2024 Jul;13(7):770-781. doi: 10.1002/cpdd.1400. Epub 2024 Apr 9. Clin Pharmacol Drug Dev. 2024. PMID: 38591154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters